See more : South Jersey Industries, Inc (SJIJ) Income Statement Analysis – Financial Results
Complete financial analysis of Endexx Corporation (EDXC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Endexx Corporation, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Jaguar Global Growth Corporation I (JGGCR) Income Statement Analysis – Financial Results
- Cayson Acquisition Corp Unit (CAPNU) Income Statement Analysis – Financial Results
- Nihon M&A Center Holdings Inc. (2127.T) Income Statement Analysis – Financial Results
- China Shenhua Energy Company Limited (601088.SS) Income Statement Analysis – Financial Results
- Hugo Boss AG (BOSS.SW) Income Statement Analysis – Financial Results
Endexx Corporation (EDXC)
About Endexx Corporation
Endexx Corporation engages in the manufacturing and sale of cannabidiol (CBD)-based products for the health and wellness market. It provides CBD creams, oils, capsules, extracts, topicals, drinks, chocolates, and pet products, as well as hemp-derived health and beauty care products for supporting the therapeutic relief of pain and inflammation for humans and pets through its e-commerce site cbdunlimited.com, as well as other online and in-store retailers. The company was formerly known as CBD Unlimited, Inc. and changed its name to Endexx Corporation in May 2020. Endexx Corporation is headquartered in Cave Creek, Arizona.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 3.91M | 1.28M | 650.52K | 1.97M | 1.50M | 797.55K | 418.39K | 220.76K | 126.26K | 34.64K | 0.00 |
Cost of Revenue | 5.06M | 774.57K | 994.59K | 606.62K | 823.58K | 449.25K | 212.46K | 166.54K | 115.72K | 732.00 | 0.00 |
Gross Profit | -1.15M | 503.01K | -344.08K | 1.36M | 674.49K | 348.30K | 205.93K | 54.22K | 10.54K | 33.91K | 0.00 |
Gross Profit Ratio | -29.39% | 39.37% | -52.89% | 69.22% | 45.02% | 43.67% | 49.22% | 24.56% | 8.35% | 97.89% | 0.00% |
Research & Development | 5.25K | 27.07K | 10.15K | 15.27K | 20.72K | 43.64K | 8.11K | 18.74K | 57.47K | 115.99K | 2.00K |
General & Administrative | 0.00 | 3.25M | 3.22M | 3.50M | 3.30M | 1.06M | 449.88K | 763.69K | 879.84K | 533.87K | 234.70K |
Selling & Marketing | 0.00 | 564.08K | 1.78M | 445.14K | 255.90K | 108.10K | 52.27K | 41.83K | 36.97K | 59.38K | 0.00 |
SG&A | 4.09M | 3.82M | 5.00M | 3.95M | 3.30M | 1.17M | 502.14K | 805.53K | 916.82K | 593.25K | 234.70K |
Other Expenses | 0.00 | 20.61K | 20.40K | 15.45K | 25.18K | 65.05K | 2.64K | 2.64K | 67.72K | 35.78K | -599.00 |
Operating Expenses | 4.09M | 3.87M | 5.03M | 3.98M | 3.35M | 1.22M | 512.90K | 826.92K | 976.72K | 710.32K | 237.07K |
Cost & Expenses | 9.15M | 4.64M | 6.02M | 4.59M | 4.17M | 1.67M | 725.36K | 993.45K | 1.09M | 710.32K | 237.07K |
Interest Income | 0.00 | 1.24M | 950.55K | 3.13M | 1.48M | 0.00 | 0.00 | 0.00 | 0.00 | 2.00 | 0.00 |
Interest Expense | 3.80M | 1.24M | 950.55K | 3.13M | 1.90M | 435.72K | 306.75K | 3.97K | 270.99K | 2.00 | 0.00 |
Depreciation & Amortization | 9.67K | 20.61K | 20.40K | 15.45K | 17.42K | 10.64K | 2.64K | 2.64K | 2.43K | 1.08K | -374.00 |
EBITDA | -4.67M | -3.65M | -5.37M | -5.73M | -6.78M | -1.33M | -276.13K | -770.05K | -896.03K | -674.60K | -236.70K |
EBITDA Ratio | -119.45% | -352.65% | -1,020.65% | -146.48% | -585.00% | -100.28% | -72.74% | -348.83% | -709.65% | -2,616.83% | 0.00% |
Operating Income | -5.24M | -3.36M | -5.37M | -2.62M | -2.67M | -867.48K | -306.97K | -772.70K | -966.18K | -675.68K | -237.07K |
Operating Income Ratio | -134.08% | -263.17% | -825.70% | -132.73% | -178.50% | -108.77% | -73.37% | -350.02% | -765.21% | -1,950.57% | 0.00% |
Total Other Income/Expenses | -3.23M | -1.23M | -1.44M | -5.45M | -3.99M | -1.63M | -361.76K | -3.97K | -84.16K | 267.66K | -599.00 |
Income Before Tax | -8.47M | -4.13M | -6.81M | -8.06M | -9.66M | -1.74M | -668.73K | -776.66K | -1.17M | -408.02K | -237.67K |
Income Before Tax Ratio | -216.81% | -323.19% | -1,046.58% | -409.01% | -644.73% | -217.94% | -159.83% | -351.82% | -926.20% | -1,177.88% | 0.00% |
Income Tax Expense | -1.98M | 766.71K | 950.55K | 3.13M | 1.73M | -434.95K | 306.75K | -1.00 | 338.71K | -231.87K | 747.00 |
Net Income | -6.50M | -4.90M | -7.76M | -11.19M | -11.39M | -1.74M | -668.73K | -776.66K | -1.17M | -408.02K | -237.67K |
Net Income Ratio | -166.26% | -383.20% | -1,192.70% | -567.92% | -760.28% | -217.94% | -159.83% | -351.82% | -926.20% | -1,177.89% | 0.00% |
EPS | -0.01 | -0.01 | -0.02 | -0.03 | -0.03 | -0.01 | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 |
EPS Diluted | -0.01 | -0.01 | -0.02 | -0.03 | -0.03 | -0.01 | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 |
Weighted Avg Shares Out | 504.71M | 503.98M | 455.05M | 379.17M | 343.49M | 289.10M | 259.70M | 235.54M | 216.32M | 211.71M | 199.04M |
Weighted Avg Shares Out (Dil) | 504.71M | 503.98M | 455.05M | 379.17M | 343.49M | 289.10M | 262.47M | 235.54M | 216.32M | 211.71M | 199.04M |
Endexx Shareholder Update Highlights Projected Momentum and Growth Rate for 2024
Endexx Featured on Small Cap Voice
Endexx Announces Strategic Partnership With Italy-Based Marketing Firm XVI Ventures
Endexx Secures Reorder for Non-Nicotine Vape Product HYLA From Italy
Endexx Announces Amended Consolidated 10-Q/A: Quarterly Report for The Quarter Ending March 31, 2023, Increasing Year-Over-Year 1013%
Endexx Announces Company Presentation in Michigan on October 2nd, 2023
Endexx Provides Insight on Possible New Federal Cannabis Regulations
Endexx Corporation Appoints Ahmed Itani to Director of Marketing of HYLA in The Middle East Region
Endexx Secures $2.0M Purchase Order for Non-Nicotine Vape Product HYLA From Sahara Trading UAE
Endexx Corporation Announces Live Twitter Spaces Q/A & Fireside Chat with C-Suite
Source: https://incomestatements.info
Category: Stock Reports